2017.HSA.doxorubicin.AC.vs.ADTIC - 版本历史

Comcat：/* 摘要 */

2024-06-28T08:13:02Z

‎摘要

Comcat：/* Reference */

2024-06-27T06:35:20Z

‎Reference

Comcat：/* Reference */

2024-06-27T06:34:07Z

‎Reference

2024年6月26日 (三) 13:41 Comcat

2024-06-26T13:41:39Z

Comcat：/* Reference */

2024-06-26T10:25:09Z

‎Reference

Comcat：/* Reference */

2024-06-26T10:05:49Z

‎Reference

Comcat：/* Reference */

2024-06-26T06:31:11Z

‎Reference

Comcat：/* Reference */

2024-06-26T06:31:01Z

‎Reference

Comcat：/* 治疗方案 (Treatment protocol) */

2024-06-26T05:57:27Z

‎治疗方案 (Treatment protocol)

Comcat：/* 讨论 (Discussion) */

2024-06-26T03:59:38Z

‎讨论 (Discussion)

@@ 第7行： / 第7行： @@
 == 摘要 ==
-犬血管肉瘤 （HSA） 是一种血管内皮起源的肿瘤，具有侵袭性生物学行为，在诊断后 12 个月内存活的狗不到 10%。首选的治疗包括手术，然后以阿霉素为基础的辅助化疗。我们前瞻性地比较了阿霉素和达卡巴嗪（ADTIC）辅助治疗与传统的多柔比星和环磷酰胺（AC）治疗，旨在确定安全性并评估该方案是否能延长生存期和转移时间（TTM）。招募了 27 只狗;分期检查后，18 例接受 AC 治疗，9 例接受 ADTIC 治疗。与接受AC治疗的狗相比，接受ADTIC治疗的狗的中位TTM和生存时间更长（分别为>550天和112天，P=0.021和>550天和142天，P=0.011）。两种方案的耐受性都很好，不需要减少剂量或增加治疗间隔。由多柔比星和达卡巴嗪联合组成的方案在患有 HSA 的狗中是安全的，并延长了 TTM 和生存时间。
+犬血管肉瘤 （HSA） 是一种血管内皮起源的肿瘤，具有侵袭性生物学行为，在诊断后 12 个月内存活的狗不到 10%。首选的治疗包括手术，然后以阿霉素为基础的辅助化疗。我们前瞻性地比较了阿霉素和达卡巴嗪（ADTIC）辅助治疗与传统的多柔比星和环磷酰胺（AC）治疗，旨在确定安全性并评估该方案是否能延长生存期和转移时间（TTM）。招募了 27 只狗;分期检查后，18 例接受 AC 治疗，9 例接受 ADTIC 治疗。与接受 AC 治疗的狗相比，接受 ADTIC 治疗的狗的中位 TTM 和生存时间更长（分别为 >550 天 对 112 天，>550 天 P=0.021 对 142 天 P=0.011）。两种方案的耐受性都很好，不需要减少剂量或增加治疗间隔。由多柔比星和达卡巴嗪联合组成的方案在患有 HSA 的狗中是安全的，并延长了 TTM 和生存时间。
 Canine hemangiosarcoma (HSA) is a neoplasm of vascular endothelial origin that has an aggressive biological behaviour, with less than 10% of dogs alive at 12-months postdiagnosis. Treatment of choice consists of surgery followed by adjuvant doxorubicin-based chemotherapy. We prospectively compared adjuvant doxorubicin and dacarbazine (ADTIC) to a traditional doxorubicin and cyclophosphamide (AC) treatment, aiming at determining safety and assessing whether this regimen prolongs survival and time to metastasis (TTM). Twenty-seven dogs were enrolled; following staging work-up, 18 were treated with AC and 9 with ADTIC. Median TTM and survival time were longer for dogs treated with ADTIC compared with those receiving AC (>550 versus 112 days, P = 0.021 and >550 versus 142 days, P = 0.011, respectively). Both protocols were well tolerated, without need for dose reduction or increased interval between treatments. A protocol consisting of combined doxorubicin and dacarbazine is safe in dogs with HSA and prolongs TTM and survival time.

@@ 第268行： / 第268行： @@
 * 2013: [[狗狗原发性心脏血管肉瘤的流行病学、临床和病理特征：51例的回顾]]。兽医学杂志 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3942993/ Epidemiological, clinical and pathological features of primary cardiac hemangiosarcoma in dogs: a review of 51 cases.]
 * 2014: [http://wiki.jackslab.org/2014.Doxorubicin.HSA 阿霉素化疗治疗狗的推定性心脏血管肉瘤] [https://pubmed.ncbi.nlm.nih.gov/25524594 Doxorubicin chemotherapy for presumptive cardiac hemangiosarcoma in dogs]
 * 2017: [http://wiki.jackslab.org/2017.HSA.doxorubicin.AC.vs.ADTIC 多柔比星-环磷酰胺与多柔比星-达卡巴嗪辅助治疗犬血管肉瘤的比较] [https://pubmed.ncbi.nlm.nih.gov/25623994/ Comparison of doxorubicin-cyclophosphamide with doxorubicin-dacarbazine for HSA]
 * 2018: [[犬内脏血管肉瘤单独手术治疗或手术加多柔比星治疗：37例（2005-2014年）]] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6091137/ Canine visceral hemangiosarcoma treated with surgery alone or surgery and doxorubicin: 37 cases (2005–2014)]

←上一版本		2024年6月27日 (四) 06:34的版本
第269行：		第269行：
	* 2014: [http://wiki.jackslab.org/2014.Doxorubicin.HSA 阿霉素化疗治疗狗的推定性心脏血管肉瘤] [https://pubmed.ncbi.nlm.nih.gov/25524594 Doxorubicin chemotherapy for presumptive cardiac hemangiosarcoma in dogs]		* 2014: [http://wiki.jackslab.org/2014.Doxorubicin.HSA 阿霉素化疗治疗狗的推定性心脏血管肉瘤] [https://pubmed.ncbi.nlm.nih.gov/25524594 Doxorubicin chemotherapy for presumptive cardiac hemangiosarcoma in dogs]
	* 2017: [http://wiki.jackslab.org/2017.HSA.doxorubicin.AC.vs.ADTIC 多柔比星-环磷酰胺与多柔比星-达卡巴嗪辅助治疗犬血管肉瘤的比较] [https://pubmed.ncbi.nlm.nih.gov/25623994/ Comparison of doxorubicin-cyclophosphamide with doxorubicin-dacarbazine for HSA]		* 2017: [http://wiki.jackslab.org/2017.HSA.doxorubicin.AC.vs.ADTIC 多柔比星-环磷酰胺与多柔比星-达卡巴嗪辅助治疗犬血管肉瘤的比较] [https://pubmed.ncbi.nlm.nih.gov/25623994/ Comparison of doxorubicin-cyclophosphamide with doxorubicin-dacarbazine for HSA]
		+	* 2018: [[犬内脏血管肉瘤单独手术治疗或手术加多柔比星治疗：37例（2005-2014年）]] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6091137/ Canine visceral hemangiosarcoma treated with surgery alone or surgery and doxorubicin: 37 cases (2005–2014)]

←上一版本		2024年6月26日 (三) 13:41的版本
第1行：		第1行：
−	多柔比星-环磷酰胺与多柔比星-~~达卡巴肼辅助治疗犬血管肉瘤的比较~~	+	多柔比星-环磷酰胺与多柔比星-达卡巴嗪辅助治疗犬血管肉瘤的比较

	Comparison of doxorubicin-cyclophosphamide with doxorubicin-dacarbazine for the adjuvant treatment of canine hemangiosarcoma		Comparison of doxorubicin-cyclophosphamide with doxorubicin-dacarbazine for the adjuvant treatment of canine hemangiosarcoma

@@ 第264行： / 第264行： @@
-* 2000: [https://pubmed.ncbi.nlm.nih.gov/11012108/ Treatment of canine hemangiosarcoma: 2000 and beyond. Journal of Veterinary Internal Medicine 2000][[犬血管肉瘤的治疗：2000 年及以后]]兽医内科杂志
+* 2000: [[犬血管肉瘤的治疗：2000 年及以后]]兽医内科杂志 [https://pubmed.ncbi.nlm.nih.gov/11012108/ Treatment of canine hemangiosarcoma: 2000 and beyond. Journal of Veterinary Internal Medicine 2000]
-* 2014: [https://pubmed.ncbi.nlm.nih.gov/25524594 Doxorubicin chemotherapy for presumptive cardiac hemangiosarcoma in dogs] [http://wiki.jackslab.org/2014.Doxorubicin.HSA 阿霉素化疗治疗狗的推定性心脏血管肉瘤]
-* 2017: [https://pubmed.ncbi.nlm.nih.gov/25623994/ Comparison of doxorubicin-cyclophosphamide with doxorubicin-dacarbazine for HSA] [http://wiki.jackslab.org/2017.HSA.doxorubicin.AC.vs.ADTIC 多柔比星-环磷酰胺与多柔比星-达卡巴嗪辅助治疗犬血管肉瘤的比较]
-−
-−
-* 2013: [[狗狗原发性心脏血管肉瘤的流行病学、临床和病理特征：51例的回顾]]。兽医学杂志 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3942993/ Epidemiological, clinical and pathological features of primary cardiac hemangiosarcoma in dogs: a review of 51 cases. 2013]
 * 2010: [[狗的胸腔镜次全心包切除术和右心房肿块切除术]]

←上一版本		2024年6月26日 (三) 06:31的版本
第261行：		第261行：

	* [30] The calculation of actual or received dose intensity: a comparison of published methods. Journal of Clinical Oncology 1991		* [30] The calculation of actual or received dose intensity: a comparison of published methods. Journal of Clinical Oncology 1991
−

@@ 第265行： / 第265行： @@
-* [https://pubmed.ncbi.nlm.nih.gov/25524594 Doxorubicin chemotherapy for presumptive cardiac hemangiosarcoma in dogs 2014] [http://wiki.jackslab.org/2014.Doxorubicin.HSA 阿霉素化疗治疗狗的推定性心脏血管肉瘤]
+* 2000: [https://pubmed.ncbi.nlm.nih.gov/11012108/ Treatment of canine hemangiosarcoma: 2000 and beyond. Journal of Veterinary Internal Medicine 2000] [[犬血管肉瘤的治疗：2000 年及以后]] 兽医内科杂志
-* [https://pubmed.ncbi.nlm.nih.gov/25623994/ Comparison of doxorubicin-cyclophosphamide with doxorubicin-dacarbazine for HSA 2017] [http://wiki.jackslab.org/2017.HSA.doxorubicin.AC.vs.ADTIC 多柔比星-环磷酰胺与多柔比星-达卡巴嗪辅助治疗犬血管肉瘤的比较]
+* 2014: [https://pubmed.ncbi.nlm.nih.gov/25524594 Doxorubicin chemotherapy for presumptive cardiac hemangiosarcoma in dogs] [http://wiki.jackslab.org/2014.Doxorubicin.HSA 阿霉素化疗治疗狗的推定性心脏血管肉瘤]
 * [b] Hill’s Neoplasia Diet, Hill’s Pet Nutrition, Topeka, KS
 * [https://todaysveterinarypractice.com/nutrition/nutritional-management-of-veterinary-patients-with-neoplasia/ Nutritional Management of Patients with Neoplasia] [[小动物肿瘤患者的营养管理]]
 <br>

@@ 第69行： / 第69行： @@
 '''标准止吐治疗''' 从化疗第一天开始连续 3 天以 2 mg/kg q24h 的剂量口服'''马罗匹坦 (maropitant)'''（赛瑞宁 Cerenia®、Pfizer、Latina、Italy）。
-'''克拉维酸增强阿莫西林'''（Synulox®，辉瑞，拉丁，意大利）以 12.5-20 mg/kg q12h 的频率预防性口服给药，直到预期的中性粒细胞减少性最低点。抗生素剂量取决于临床医生的偏好。
+'''克拉维酸增强阿莫西林'''（速诺 Synulox®，辉瑞，拉丁，意大利）以 12.5-20 mg/kg q12h 的频率预防性口服给药，直到预期的中性粒细胞减少性最低点。抗生素剂量取决于临床医生的偏好。
 </source>

←上一版本		2024年6月26日 (三) 03:59的版本
第227行：		第227行：

	此外，除了其细胞毒性活性外，达卡巴嗪已被证明在小鼠中具有抗转移特性，其潜在机制与其增强肿瘤免疫原性的能力有关[38,39]。在这项研究中，用 ADTIC 治疗的狗具有更长的 TTM，这可能反映了达卡巴嗪抑制转移扩散的能力，或者是因为研究的样本量小。		此外，除了其细胞毒性活性外，达卡巴嗪已被证明在小鼠中具有抗转移特性，其潜在机制与其增强肿瘤免疫原性的能力有关[38,39]。在这项研究中，用 ADTIC 治疗的狗具有更长的 TTM，这可能反映了达卡巴嗪抑制转移扩散的能力，或者是因为研究的样本量小。
		+

	This could have multiple explanations. In this study, the total intended dose of dacarbazine was divided into five daily boluses, whereas in the DAV study this was administered as a single dose over 8-h infusion; in fact, it has been suggested that daily dacarbazine IV boluses may cause reduced gastrointestinal toxicity than slow IV infusions, without negatively affecting antitumour activity.16,28 Moreover, vincristine was not administered in ADTIC dogs, possibly reducing the risk of gastrointestinal toxicity. It should also be noted that the majority of dogs included in group 2 presented with no advanced clinical stage, whereas in the DAV study dogs were most likely to have stage III disease; dogs with advanced disease could easily have reduced performance status, potentially leading to enhanced susceptibility to chemotherapy toxicity.35		This could have multiple explanations. In this study, the total intended dose of dacarbazine was divided into five daily boluses, whereas in the DAV study this was administered as a single dose over 8-h infusion; in fact, it has been suggested that daily dacarbazine IV boluses may cause reduced gastrointestinal toxicity than slow IV infusions, without negatively affecting antitumour activity.16,28 Moreover, vincristine was not administered in ADTIC dogs, possibly reducing the risk of gastrointestinal toxicity. It should also be noted that the majority of dogs included in group 2 presented with no advanced clinical stage, whereas in the DAV study dogs were most likely to have stage III disease; dogs with advanced disease could easily have reduced performance status, potentially leading to enhanced susceptibility to chemotherapy toxicity.35